Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD
Colin Rutherford
Our Products
phexx
®
Solosec
®
Publications
PHEXX
SOLOSEC
Investors
Investor Overview
Why Invest
Events & Presentations
Press Releases
Stock Information
Financial Information
Quarterly Results
SEC Filings
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Email Alerts
Information Request Form
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Timing of On-Study Pregnancies with a Vaginal pH Modulator in the Phase 3 AMPOWER Trial
Post navigation
Previous:
Side Effects by Frequency of Use with EVO100 Vaginal Gel: Results From The Phase 2B/3 AMPREVENCE Trial.
Next:
Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study
Back
to
Top
